Vas Narasimhan, Novartis CEO (Simon Dawson/Bloomberg via Getty Images)
It's a year late, but Novartis has finally steered inclisiran to FDA approval. Will it sell?
The centerpiece of Novartis’s $9.7 billion buyout of the Medicines Company can finally go to market.
Branded Leqvio, the small interfering RNA therapy long …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
